Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes

David H. Lerner Investing Group Leader Follow Summary Biotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds subside, driving sector-wide rallies. Stabilization at the FDA and a resurgence in M&A and IPO activity are restoring capital flows and investor confidence in biotech equities. Individual stock selection in biotech, targeting under-addressed diseases, has outperformed broad ETFs like IBB and XBI in recent months. Names like ABCL, LBRX, QURE, and CADL exemplify outsized returns as positive clinical news and improved market conditions catalyze sharp re-ratings. This idea was discussed in more depth with members of my private investing community, The Active Investors Forum. Learn More » simonkr/E+ via Getty Images Biotech and All Areas of Healthcare Had Been Lagging in This Bull Market All that has changed, and if you want to invest in growth away from AI, biotech might be where you want to be. This article was written by David H. Lerner 31.92K Followers Follow David H. Lerner is an analyst with a decade of experience utilizing his professional background in software consulting and technology to identify market trends and provide long and short trade ideas. David employs a combination of technical analysis and market psychology to capitalize on narratives for outsized returns. He also utilizes “Cash Management Discipline,” a simple trading style to hedge against the volatility of today’s market climate.He leads the investing group Active Investors Forum where he uncovers actionable trading and investing ideas nearly every day. Other features include: long and short swing trade alerts, daily macro analysis, weekly articles, and chat for community interaction and questions. Learn More. Analyst’s Disclosure: I/we have a beneficial long position in the shares of ABCL either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.